China At ASCO: Biotech Pharma, Akeso, Chongqing Precision Showcase Promising Data
Oncology Rise Continues
EGFR-targeting antibody, anti-PD-1/CTLA4 bispecific antibody and CD19-targeting CAR-T therapy from emerging Chinese oncology companies shine at one of ASCO’s most-watched sessions.
You may also be interested in...
After slashing the prices of their blockbuster drugs to gain wider patient access through China's main reimbursement program, multinationals are now beginning to face increasing challenges from local competitors.
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.
Oversee returnee-founded Chinese biotech start-ups Nuwacell and Arnatar secure $14m in series A and seed rounds respectively, while four other major deals backed by private equity and venture capital firms raise a combined $116m.